HANSHOW/INTERGAMMA
Hanshow, a global leader in digital retail solutions, has announced its exclusive partnership with Intergamma, the market leader in the Benelux DIY sector, initiating the official installation of Hanshow's Electronic Shelf Labels (ESLs) in November 2023. This collaboration aims to deliver a unique and seamless shopping experience for customers across all channels. This collaboration signals an exciting development in the retail industry as it expands Hanshow's presence in the non-food retail sector with Intergamma operating under the prominent Gamma and Karwei brands, with nearly 400 stores in the Netherlands and Belgium. As of February 2024, installation progress includes the successful completion of ESL deployments in all 128 Karwei stores, with installations for Gamma outlets actively ongoing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240504881462/en/
Hanshow ESLs at Intergamma. (Photo: Business Wire)
Joining forces with Hanshow and utilizing the cutting-edge electronic shelf label (ESL) solution, Intergamma will further streamline in-store operations and enhance the customer journey in its stores for certain categories. As the largest DIY online platform in the Benelux region, Intergamma is committed to breaking boundaries and offering seamless shopping from online search to in-store purchases. Hanshow's ESL solution provides real-time synchronization of product information and pricing across all channels, reducing pricing discrepancies and improving the overall in-store experience.
This partnership marks a significant milestone for both companies. Through this alliance, Intergamma will leverage Hanshow's ESL technology to provide customers with an enhanced smart shopping experience for selected categories.
The key advantages of Hanshow's ESL solutions include:
- Innovation in ESL: Hanshow is at the forefront of ESL technology, offering holistic ESL solutions specifically for the DIY industry.
- Technology Leadership: Hanshow's new generation HiLPC protocol offers retailers top-tier ESL management, rapid response times, reliable service, and precise cross-channel pricing to enhance O2O capabilities.
- Industry Expertise: Leveraging extensive experience in the DIY sector, Hanshow aids Intergamma in advancing its digital transformation efforts.
Intergamma's values of fostering a sustainable future is also aligned with the introduction of Hanshow's eco-friendly operational model.
Jurre Mulder, Chief Digital & Technology Officer at Intergamma said, “We are happy to announce our partnership with renowned supplier digital store solutions Hanshow. Through this collaboration, Intergamma demonstrates its dedication to incorporating cutting-edge technology and improving the shopping experience for its devoted customers. In the next 9 months we will roll out ESL in our stores for the paint and electrical tools departments. We're excited to raise the bar for retail innovation together.”
“This collaboration with Intergamma is an important milestone in our journey to expand into the DIY retail field,” said Liangyan Li, SVP, Head of Global Sales, Hanshow. “This partnership is a great starting point, and in the future, Intergamma and Hanshow will continue to collaborate deeply, accelerating innovation and integration, and jointly promoting the digitization and sustainable development of the DIY retail industry.”
About Intergamma
Intergamma B.V. is the market leader in the do-it-yourself market in the Benelux with its retail formulas GAMMA Netherlands, GAMMA Belgium and KARWEI. With a strong store network and cross-channel strategy, Intergamma inspires and helps its customers to turn their house and garden into a comfortable and sustainable home. Learn more: www.intergamma.nl
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240504881462/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom